SOMAKIT TOC (68Ga-edotreotide), radiopharmaceutical for diagnostic use

DIAGNOSIS - New medicinal product

Opinions on drugs - Posted on Nov 15 2017

Inclusion

SOMAKIT TOC has Marketing Authorisation in the diagnosis of neuroendocrine tumours.
It is intended for positron emission tomography (PET) and binds specifically to somatostatin receptors.
Studies have not demonstrated any benefit in relation to its clinically relevant comparators.

Substantial

no clinical added value

Therapeutic use

Évaluation des médicaments

All our publications

My account